Table 1.

Baseline characteristics and prior treatment history

CharacteristicAll treated (N = 85)Lenalidomide refractory (n = 51)
Age, median (range), y 66 (38-85) 66 (38-85) 
ECOG performance status   
 0-1 78 (92) 47 (92) 
 2 7 (8) 4 (8) 
No. of prior lines   
 Median (range) 2 (1-4) 2 (1-4) 
 1 20 (24) 6 (12) 
 2 40 (47) 26 (51) 
 3 23 (27) 18 (35) 
 >3 2 (2) 1 (2) 
Prior ASCT 62 (73) 33 (65) 
Prior bortezomib 85 (100) 51 (100) 
Prior IMiD 85 (100) 51 (100) 
 Lenalidomide 81 (95) 51 (100) 
 Pomalidomide 13 (15) 9 (18) 
 Thalidomide 21 (25) 11 (22) 
Refractory to:*   
 Lenalidomide 51 (60) 51 (100) 
 Pomalidomide 11 (13) 9 (18) 
 Bortezomib 26 (31) 21 (41) 
 PI + IMiD 25 (29) 22 (43) 
CharacteristicAll treated (N = 85)Lenalidomide refractory (n = 51)
Age, median (range), y 66 (38-85) 66 (38-85) 
ECOG performance status   
 0-1 78 (92) 47 (92) 
 2 7 (8) 4 (8) 
No. of prior lines   
 Median (range) 2 (1-4) 2 (1-4) 
 1 20 (24) 6 (12) 
 2 40 (47) 26 (51) 
 3 23 (27) 18 (35) 
 >3 2 (2) 1 (2) 
Prior ASCT 62 (73) 33 (65) 
Prior bortezomib 85 (100) 51 (100) 
Prior IMiD 85 (100) 51 (100) 
 Lenalidomide 81 (95) 51 (100) 
 Pomalidomide 13 (15) 9 (18) 
 Thalidomide 21 (25) 11 (22) 
Refractory to:*   
 Lenalidomide 51 (60) 51 (100) 
 Pomalidomide 11 (13) 9 (18) 
 Bortezomib 26 (31) 21 (41) 
 PI + IMiD 25 (29) 22 (43) 

Unless otherwise noted, all data are n (%).

*

Refractoriness was based on most recent prior medication.

or Create an Account

Close Modal
Close Modal